(ACAD) ACADIA Pharmaceuticals - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.692m USD | Total Return: -2.7% in 12m
Avg Turnover: 27.6M
Qual. Beats: 0
Rev. Trend: 93.5%
Qual. Beats: -2
Warnings
Earnings expected to drop: P/E 9.8 → Forward 62.5
Tailwinds
No distinct edge detected
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for central nervous system (CNS) disorders and rare diseases. The company’s commercial portfolio includes NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome. Its research pipeline spans Phase 1 and Phase 2 trials targeting Alzheimer’s disease psychosis, major depressive disorder, and Huntington’s disease.
The biotechnology sector typically requires high research and development (R&D) expenditures and relies on patent protections to secure market exclusivity for novel molecular entities. ACADIA utilizes a business model centered on strategic licensing agreements, such as its partnerships with Neuren Pharmaceuticals and Stoke Therapeutics, to expand its intellectual property and therapeutic reach.
Investors should examine the fundamental metrics on ValueRay to better understand the companys valuation.
- NUPLAZID market share in Parkinsons disease psychosis remains the primary revenue driver
- DAYBUE adoption rates in Rett syndrome dictate short-term commercial growth trajectory
- R&D pipeline expansion into Alzheimer’s and Lewy body dementia impacts valuation
- Regulatory approval hurdles for new indications pose significant clinical development risk
- Strategic licensing agreements and royalty obligations influence long-term operating margins
| Net Income: 375.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 8.85 > 1.0 |
| NWC/Revenue: 72.17% < 20% (prev 57.05%; Δ 15.12% < -1%) |
| CFO/TA 0.08 > 3% & CFO 123.5m > Net Income 375.6m |
| Net Debt (-800.7m) to EBITDA (92.7m): -8.64 < 3 |
| Current Ratio: 3.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.7m) vs 12m ago 3.00% < -2% |
| Gross Margin: 91.47% > 18% (prev 92.04%; Δ -0.57% > 0.5%) |
| Asset Turnover: 80.02% > 50% (prev 87.98%; Δ -7.97% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.49 (Total Current Assets 1.10b - Total Current Liabilities 305.5m) / Total Assets 1.61b |
| B: -1.13 (Retained Earnings -1.81b / Total Assets 1.61b) |
| C: 0.06 (EBIT TTM 80.9m / Avg Total Assets 1.37b) |
| D: 3.49 (Book Value of Equity 1.25b / Total Liabilities 357.2m) |
| Altman-Z'' = 3.62 = AA |
| DSRI: 1.08 (Receivables 135.3m/113.7m, Revenue 1.10b/996.3m) |
| GMI: 1.01 (GM 92.04% / 91.47%) |
| AQI: 1.53 (AQ_t 0.28 / AQ_t-1 0.18) |
| SGI: 1.10 (Revenue 1.10b / 996.3m) |
| TATA: 0.16 (NI 375.6m - CFO 123.5m) / TA 1.61b) |
| Beneish M = -2.55 (Cap -4..+1) = A |
As of June 09, 2026, the stock is trading at USD 21.70 with a total of 883,774 shares traded.
Over the past week, the price has changed by +0.84%,
over one month by -3.12%,
over three months by -3.90% and
over the past year by -2.69%.
ACADIA Pharmaceuticals has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy ACAD.
- StrongBuy: 7
- Buy: 6
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 31.7 | 45.9% |
P/E Trailing = 9.7557
P/E Forward = 62.5
P/S = 3.3708
P/B = 2.9581
P/EG = 50.8642
Revenue TTM = 1.10b USD
EBIT TTM = 80.9m USD
EBITDA TTM = 92.7m USD
Long Term Debt = 39.0m USD (estimated: total debt 50.8m - short term 11.8m)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 50.8m USD (from shortLongTermDebtTotal, last quarter) (leases 50.8m already included)
Net Debt = -800.7m USD (calculated: Debt 50.8m - CCE 851.5m)
Enterprise Value = 2.89b USD (3.69b + Debt 50.8m - CCE 851.5m)
Interest Coverage Ratio = unknown (Ebit TTM 80.9m / Interest Expense TTM 0.0)
EV/FCF = 13.61x (Enterprise Value 2.89b / FCF TTM 212.4m)
FCF Yield = 7.35% (FCF TTM 212.4m / Enterprise Value 2.89b)
FCF Margin = 19.40% (FCF TTM 212.4m / Revenue TTM 1.10b)
Net Margin = 34.30% (Net Income TTM 375.6m / Revenue TTM 1.10b)
Gross Margin = 91.47% ((Revenue TTM 1.10b - Cost of Revenue TTM 93.4m) / Revenue TTM)
Gross Margin QoQ = 90.75% (prev 90.77%)
Tobins Q-Ratio = 1.80 (Enterprise Value 2.89b / Total Assets 1.61b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 50.8m)
Taxrate = 8.64% (344k / 3.98m)
NOPAT = 73.9m (EBIT 80.9m * (1 - 8.64%))
Current Ratio = 3.59 (Total Current Assets 1.10b / Total Current Liabilities 305.5m)
Debt / Equity = 0.04 (Debt 50.8m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = -8.64 (Net Debt -800.7m / EBITDA 92.7m)
Debt / FCF = -3.77 (Net Debt -800.7m / FCF TTM 212.4m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.44% (Net Income 375.6m / Total Assets 1.61b)
RoE = 35.65% (Net Income TTM 375.6m / Total Stockholder Equity 1.05b)
RoCE = 7.40% (EBIT 80.9m / Capital Employed (Equity 1.05b + L.T.Debt 39.0m))
RoIC = 5.88% (NOPAT 73.9m / Invested Capital 1.26b)
WACC = 9.75% (E(3.69b)/V(3.74b) * Re(9.88%) + D(50.8m)/V(3.74b) * Rd(0.0%) * (1-Tc(0.09)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 1.64%
[DCF] Terminal Value 73.59% ; FCFF base≈147.3m ; Y1≈168.9m ; Y5≈248.5m
[DCF] Fair Price = 22.20 (EV 3.00b - Net Debt -800.7m = Equity 3.80b / Shares 171.2m; r=9.75% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.27 | # QB: 0
Revenue Correlation: 93.47 | Revenue CAGR: 25.71% | SUE: -1.84 | # QB: -2
EPS current Quarter (2026-06-30): EPS=0.04 | Chg30d=-66.19% | Revisions=-40% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.12 | Chg30d=+1.82% | Revisions=+20% | Analysts=11
EPS current Year (2026-12-31): EPS=0.40 | Chg30d=-18.00% | Revisions=-54% | GrowthEPS=-52.1% | GrowthRev=+15.8%
EPS next Year (2027-12-31): EPS=0.89 | Chg30d=-5.88% | Revisions=-40% | GrowthEPS=+124.8% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: -54%